Micromem Technologies Inc. Provides Update on Liquid-Sensing Technology Development
MWN-AI** Summary
Micromem Technologies Inc. (CSE: MRM, OTCQB: MMTIF) recently provided a promising update on its liquid-sensing technology development under a collaboration with the University of Toronto and the Department of National Defence. This initiative, known as the "Development of a Nanowire Field Effect Transistor Biochemical Sensor Project," aims to enhance the detection of biochemical agents for various applications, particularly in defense and medical diagnostics.
On March 9, during a program review led by Defence Research and Development Canada and UofT, Micromem showcased significant advancements in the liquid-phase sensing platform. This technology has achieved critical milestones by successfully detecting biomarkers linked to acute inflammation and infectious diseases. Key achievements include new designs for on-chip electrodes, improved fabrication of the proprietary Nanowire Field-Effect Transistor (NWFET) devices, and optimization of photolithography processes.
The NWFET technology stands out for its nanoscale precision, enabling real-time detection of biomarkers while being ultra-sensitive and label-free, marking a significant leap from traditional methods. Notable biomarkers tested include Angiopoietin-1, a vital component for vascular health, and TREM-1, crucial for monitoring immune activation, particularly in bacterial infections like sepsis. The platform's ability to detect TREM-1 at low concentrations indicates its promising high sensitivity.
Moving forward, Micromem plans to validate additional biomarkers and finalize the integration of microfluidic systems. This dual-phase sensor development not only enhances Micromem's defense capabilities but also opens avenues for commercial medical diagnostics, including point-of-care testing. The company believes that this progress substantially increases the long-term viability of its technology, aligning with its broader strategy of creating scalable solutions informed by defense-driven innovation.
MWN-AI** Analysis
Micromem Technologies Inc. (CSE: MRM, OTCQB: MMTIF) is currently making significant strides in its liquid-phase sensor development, particularly through its collaboration with the University of Toronto and the Department of National Defence. The advancements reported in their recent update indicate a technology that not only meets technical milestones but also has the potential to disrupt the market in both defense and medical diagnostics.
The company's proprietary Nanowire Field-Effect Transistor (NWFET) technology is a key differentiator, allowing for ultra-sensitive and real-time detection of biomarkers linked to critical health conditions such as inflammation and infectious diseases. This dual application — both for defense and commercial medical diagnostics — positions Micromem favorably amidst rising demand for point-of-care testing solutions.
Investors should take note of the promising developments, including the successful detection of biomarkers like TREM-1 at low concentration levels, which suggests high sensitivity and reliability of their sensors. As Micromem continues to validate these biomarkers and integrate microfluidic systems, it is likely to enhance its offering and market appeal further.
From a market perspective, Micromem’s current trajectory, bolstered by strong technological advancements and strategic partnerships, could drive growth in investor interest. However, potential investors should remain cautious of the inherent risks outlined, such as the need for ongoing financing and market acceptance. Given this dual-use innovation's strategic importance, those considering an investment might view entering at this stage as an opportunity to capture potential future gains, particularly as the commercial applicability of their technologies unfolds.
In conclusion, Micromem Technologies presents a compelling opportunity for investors who are prepared to navigate the inherent risks of a pioneering tech firm in the biochemical sensing space. Continued monitoring of their progress and market developments will be key to making informed decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Toronto, Ontario and New York, New York--(Newsfile Corp. - March 30, 2026) - Micromem Technologies Inc. (CSE: MRM) (OTCQB: MMTIF) ("Micromem" or the "Company") is pleased to provide an update on the liquid-phase sensor development within the "Development of a Nanowire Field Effect Transistor Biochemical Sensor Project" (the "Project") under its Research Collaboration Agreement (the "Agreement") with the University of Toronto (UofT) and the Department of National Defence (DND).
On March 9, Micromem participated in a program review led by Defence Research and Development Canada (DRDC) and UofT, highlighting continued progress across the Project's two parallel platforms: gas-phase and liquid-phase sensing.
This update focuses on advancements in the liquid-phase sensor, which targets the sensitive detection of biochemical agents and offers strong potential applications in both defence and commercial medical diagnostics.
Liquid-Phase Sensor Progress
Micromem is pleased to report that the liquid-phase platform has successfully demonstrated the ability to detect clinically relevant biomarkers associated with acute inflammation and infectious disease - a significant technical milestone.
Recent development achievements include:
- Design and implementation of new mask patterns for on-chip electrodes
- Advancement in the fabrication of the Company's proprietary NWFET (Nanowire Field-Effect Transistor) devices
- Optimization of photolithography parameters and overall fabrication processes
- Progress toward full integration of portable sensing platforms with enclosed microfluidic systems
NWFET technology is a true game changer, transforming biochemical sensing with nanoscale precision that achieves ultra-sensitive, label-free, real-time detection far beyond traditional methods.
Biomarker Testing Results The research team conducted successful testing on key biomarkers, including:
- Angiopoietin-1, vascular growth factor, on endothelial cells. Maintains blood vessel maturation, stabilization, and vascular integrity. Important biomarker for vascular diseases, inflammation, and cancer
- Streptavidin-linked assays, widely used in biomolecular detection systems
- TREM-1 (Triggering Receptor Expressed on Myeloid Cells-1), an important biomarker of immune activation and inflammatory response, particularly in bacterial infections and sepsis
Notably, the platform detected TREM-1 at low concentration levels, confirming the high sensitivity of the NWFET technology. These positive results were deemed satisfactory to support advancement in the next phase of development.
Next Steps
With these milestones achieved, near-term activities will include further biomarker validation and completion of the microfluidic integration.
Strategic Importance
The liquid-phase sensor development complements Micromem's parallel gas-phase program and broadens the Company's market opportunities. Originally focused on biochemical threat detection for defence applications, the technology's proven capability in identifying clinically relevant biomarkers opens pathways into commercial medical diagnostics, including point-of-care testing.
Micromem believes this dual-use potential significantly enhances the long-term value of the platform and aligns with the Company's strategy of translating defence-driven innovation into scalable commercial solutions.
About Micromem.
Micromem Technologies Inc. and its subsidiaries, a publicly traded (OTCQB: MMTIF) (CSE: MRM), company analyzes specific industry sectors to create intelligent game-changing applications that address unmet market needs. By leveraging its expertise and experience with sophisticated sensor applications, the Company successfully powers the development and implementation of innovative solutions for oil & gas, utilities, automotive, healthcare, government, information technology, manufacturing and other industries. Visit www.micromeminc.com.
Safe Harbor Statement.
This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; continued consumer adoption of digital technology; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer and technological demands; inability to replace significant customers; seasonal nature of our business; and other risks detailed in our filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential," and similar expressions may be used to identify forward-looking statements.
The CSE or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release that has been prepared by management.
###
Listing: OTCQB - Symbol: MMTIF and CSE - Symbol: MRM
Shares issued: 626,013,781
SEC File No: 0-26005
Investor Contact: info@micromeminc.com; Tel. 416-364-2023 Subscribe to receive News Releases by Email on our website's home page. www.micromeminc.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290213
FAQ**
How does the collaboration between Micromem Technologies Inc. MMTIF and the University of Toronto enhance the development of liquid-phase sensors for medical diagnostics in Toronto?
In what ways could the advancements in Micromem's liquid-phase sensor technology impact the healthcare sector in New York, New York, particularly in terms of point-of-care testing?
Given the technological innovations from Micromem Technologies Inc. MMTIF, how might these developments influence defense and medical diagnostics markets differently in Toronto compared to New York?
What strategic advantages does Micromem’s dual-use sensor development present in the competitive landscapes of Toronto’s and New York’s biotech industries?
**MWN-AI FAQ is based on asking OpenAI questions about Micromem Technologies, Inc. (OTC: MMTIF).
NASDAQ: MMTIF
MMTIF Trading
7.18% G/L:
$0.0194 Last:
318,644 Volume:
$0.0172 Open:
MMTIF Latest News
